Preferences for Breast Cancer Risk Reduction Among BRCA1/BRCA2 Mutation Carriers: a Discrete-choice Experiment

Overview

Journal Breast Cancer Res Treat

Specialty Oncology

Date 2017 Jun 19

PMID 28624978

Citations 15

Authors

Alexander Liede

Carol A Mansfield

Kelly A Metcalfe

Melanie A Price

Carrie Snyder

Henry T Lynch

Sue Friedman

Justyna Amelio

Joshua Posner

Steven A Narod

Geoffrey J Lindeman

D Gareth Evans

Affiliations

Soon will be listed here.

Abstract

Purpose: Unaffected women who carry BRCA1 or BRCA2 mutations face difficult choices about reducing their breast cancer risk. Understanding their treatment preferences could help us improve patient counseling and inform drug trials. The objective was to explore preferences for various risk-reducing options among women with germline BRCA1/2 mutations using a discrete-choice experiment survey and to compare expressed preferences with actual behaviors.

Methods: A discrete-choice experiment survey was designed wherein women choose between hypothetical treatments to reduce breast cancer risk. The hypothetical treatments were characterized by the extent of breast cancer risk reduction, treatment duration, impact on fertility, hormone levels, risk of uterine cancer, and ease and mode of administration. Data were analyzed using a random-parameters logit model. Women were also asked to express their preference between surgical and chemoprevention options and to report on their actual risk-reduction actions. Women aged 25-55 years with germline BRCA1/2 mutations who were unaffected with breast or ovarian cancer were recruited through research registries at five clinics and a patient advocacy group.

Results: Between January 2015 and March 2016, 622 women completed the survey. Breast cancer risk reduction was the most important consideration expressed, followed by maintaining fertility. Among the subset of women who wished to have children in future, the ability to maintain fertility was the most important factor, followed by the extent of risk reduction. Many more women said they would take a chemoprevention drug than had actually taken chemoprevention.

Conclusions: Women with BRCA1/2 mutations indicated strong preferences for breast cancer risk reduction and maintaining fertility. The expressed desire to have a safe chemoprevention drug available to them was not met by current chemoprevention options.

Citing Articles

Risk-management decision-making data from a community-based sample of racially diverse women at high risk of breast cancer: rationale, methods, and sample characteristics of the Daughter Sister Mother Project survey.

Padamsee T, Bijou C, Swinehart-Hord P, Hils M, Muraveva A, Meadows R Breast Cancer Res. 2024; 26(1):8.

PMID: 38212792 PMC: 10785448. DOI: 10.1186/s13058-023-01753-x.

Patient Preferences for Lung Cancer Interception Therapy.

Janssen E, Smith I, Liu X, Pierce A, Huang Q, Kalsekar I JAMA Netw Open. 2023; 6(11):e2342681.

PMID: 37948077 PMC: 10638649. DOI: 10.1001/jamanetworkopen.2023.42681.

Evaluation of disparities in perceived healthcare discrimination among -positive women from medically underserved populations.

Dibble K, Connor A Women Health. 2023; 63(7):539-550.

PMID: 37461380 PMC: 10372883. DOI: 10.1080/03630242.2023.2237610.

Delineating the role of osteoprotegerin as a marker of breast cancer risk among women with a BRCA1 mutation.

Park S, Uzelac A, Kotsopoulos J Hered Cancer Clin Pract. 2022; 20(1):14.

PMID: 35418083 PMC: 9008947. DOI: 10.1186/s13053-022-00223-3.

Physical activity and Mediterranean diet as potential modulators of osteoprotegerin and soluble RANKL in gBRCA1/2 mutation carriers: results of the lifestyle intervention pilot study LIBRE-1.

Neirich L, Yahiaoui-Doktor M, Lammert J, Basrai M, Seethaler B, Berling-Ernst A Breast Cancer Res Treat. 2021; 190(3):463-475.

PMID: 34570303 PMC: 8558155. DOI: 10.1007/s10549-021-06400-7.

References

Widschwendter M, Burnell M, Fraser L, Rosenthal A, Philpott S, Reisel D . Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers. EBioMedicine. 2015; 2(10):1331-9. PMC: 4634624. DOI: 10.1016/j.ebiom.2015.08.037. View

Easton D, Ford D, Bishop D . Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995; 56(1):265-71. PMC: 1801337. View

Metcalfe K, Birenbaum-Carmeli D, Lubinski J, Gronwald J, Lynch H, Moller P . International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer. 2008; 122(9):2017-22. PMC: 2936778. DOI: 10.1002/ijc.23340. View

Kauff N, Satagopan J, Robson M, Scheuer L, Hensley M, Hudis C . Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002; 346(21):1609-15. DOI: 10.1056/NEJMoa020119. View

Ford D, Easton D, Stratton M, Narod S, Goldgar D, Devilee P . Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998; 62(3):676-89. PMC: 1376944. DOI: 10.1086/301749. View

Schwartz M, Peshkin B, Hughes C, Main D, Isaacs C, Lerman C . Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. J Clin Oncol. 2002; 20(2):514-20. DOI: 10.1200/JCO.2002.20.2.514. View

Fagerlin A, Zikmund-Fisher B, Ubel P . Helping patients decide: ten steps to better risk communication. J Natl Cancer Inst. 2011; 103(19):1436-43. PMC: 3218625. DOI: 10.1093/jnci/djr318. View

Warner E, Hill K, Causer P, Plewes D, Jong R, Yaffe M . Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol. 2011; 29(13):1664-9. PMC: 4874196. DOI: 10.1200/JCO.2009.27.0835. View

Lubinski J, Huzarski T, Byrski T, Lynch H, Cybulski C, Ghadirian P . The risk of breast cancer in women with a BRCA1 mutation from North America and Poland. Int J Cancer. 2011; 131(1):229-34. PMC: 3334396. DOI: 10.1002/ijc.26369. View

10.

Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E . Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013; 105(11):812-22. DOI: 10.1093/jnci/djt095. View

11.

Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik J, Lee H . Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature. 2010; 468(7320):98-102. PMC: 3084017. DOI: 10.1038/nature09387. View

12.

Sigl V, Owusu-Boaitey K, Joshi P, Kavirayani A, Wirnsberger G, Novatchkova M . RANKL/RANK control Brca1 mutation- . Cell Res. 2016; 26(7):761-74. PMC: 5129883. DOI: 10.1038/cr.2016.69. View

13.

Domchek S, Friebel T, Singer C, Evans D, Lynch H, Isaacs C . Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010; 304(9):967-75. PMC: 2948529. DOI: 10.1001/jama.2010.1237. View

14.

Thompson D, Easton D . Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet. 2001; 68(2):410-9. PMC: 1235274. DOI: 10.1086/318181. View

15.

Heemskerk-Gerritsen B, Seynaeve C, van Asperen C, Ausems M, Collee J, van Doorn H . Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst. 2015; 107(5). DOI: 10.1093/jnci/djv033. View

16.

Evans D, Harkness E, Lalloo F, Howell A . Long-term prospective clinical follow-up after BRCA1/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies. J Med Genet. 2014; 51(9):573-80. DOI: 10.1136/jmedgenet-2014-102336. View

17.

Moller P, Maehle L, Vabo A, Clark N, Sun P, Narod S . Age-specific incidence rates for breast cancer in carriers of BRCA1 mutations from Norway. Clin Genet. 2012; 83(1):88-91. DOI: 10.1111/j.1399-0004.2012.01855.x. View

18.

Metcalfe K, Poll A, Llacuachaqui M, Nanda S, Tulman A, Mian N . Patient satisfaction and cancer-related distress among unselected Jewish women undergoing genetic testing for BRCA1 and BRCA2. Clin Genet. 2010; 78(5):411-7. DOI: 10.1111/j.1399-0004.2010.01499.x. View

19.

Struewing J, Hartge P, Wacholder S, Baker S, Berlin M, McAdams M . The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997; 336(20):1401-8. DOI: 10.1056/NEJM199705153362001. View

20.

Beleut M, Rajaram R, Caikovski M, Ayyanan A, Germano D, Choi Y . Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci U S A. 2010; 107(7):2989-94. PMC: 2840294. DOI: 10.1073/pnas.0915148107. View